Macrophage production and activation are dependent on TRIM33 by Gallouet, A.-S. (Anne-Sophie) et al.
Oncotarget5111www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/                    Oncotarget, 2017, Vol. 8, (No. 3), pp: 5111-5122
Macrophage production and activation are dependent on TRIM33
Anne-Sophie Gallouet1,2,3,4,5, Federica Ferri1,2,3,4,5,6,*, Vanessa Petit1,2,3,4,5,*, Aude 
Parcelier1,2,3,4,5, Daniel Lewandowski1,2,3,4,5, Nathalie Gault1,2,3,4,5, Vilma Barroca1,2,3,4,5, 
Stéphanie Le Gras6, Eric Soler1,2,3,4,7, Frank Grosveld7, Irwin Davidson6, Paul-Henri 
Romeo1,2,3,4,5
1CEA/DRF/iRCM/LRTS, 92265 Fontenay-aux-Roses cedex, France
2Inserm U967, 92265 Fontenay-aux-Roses cedex, France
3Université Paris-Diderot, Paris 7, France
4Université Paris-Sud, Paris 11, France
5Equipe labellisée Ligue contre le Cancer, France
6Department of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/
INSERM/ULP, BP 163, 67404 Illkirch Cedex, C. U. Strasbourg, France
7Department of Cell Biology, Erasmus Medical Center, DR Molenwaterplein 50, 3015GE, Rotterdam, The Netherlands
*These authors have contributed equally to this work
Correspondence to: Paul-Henri Romeo, email: paul-henri.romeo@cea.fr
Keywords: TRIM33, PU.1, macrophage, inflammation, myeloid differentiation
Received: June 07, 2016    Accepted: November 12, 2016    Published: December 10, 2016
ABSTRACT
The tripartite motif (TRIM) family of proteins plays important roles in innate 
immunity and antimicrobial infection. None of these proteins has been shown to 
directly regulate transcription of genes in monocyte/macrophage except TRIM33 
that we have recently shown to be a macrophage specific transcriptional inhibitor 
of Ifnb1. Using ChIP-seq analyses, we now report that TRIM33 is bound to two fold 
more genes in immature than in mature myeloid cell lines. When located near the 
same genes, TRIM33 is bound to different sequences in the two cell lines suggesting 
a role of TRIM33 in both immature and mature myeloid cells. Accordingly, expression 
of TRIM33 in immature myeloid cells is necessary for efficient production of small 
peritoneal macrophages, monocytes and bone marrow derived macrophage (BMDM) 
and TRIM33 targets a subset of genes involved in the inflammatory response only 
in mature myeloid cells. Functionally, this targeting is associated with impaired 
repression of pathways regulating the late phases of lipopolysaccharide (LPS) 
activation of BMDM and a high sensitivity to LPS in vivo when the Trim33 gene is 
inactivated in mature myeloid cells. These findings pinpoint TRIM33 as an important 
transcriptional actor of monocyte/macrophage mediated inflammation.
INTRODUCTION
Inflammation requires coordinated cellular 
interactions between a variety of different cell types 
belonging to innate and adaptive immune systems and 
parenchymal cells surrounding the site of inflammation 
[1]. Macrophages are mobile hematopoietic cells that 
act as immune sentinels [2]. They reside in most organs 
and can deeply migrate within a tissue to the focus of 
inflammation [3]. In response to extracellular signals 
that activate their respective receptors, macrophages 
transcriptionally activate a complex network of genes and 
become one of the principal cellular effectors of acute and/
or chronic inflammation [4]. The initial activation state 
of macrophages results in synthesis of pro-inflammatory 
mediators with antimicrobial and/or antiviral effects, 
but persistent expression of these mediators can cause 
extensive tissue damage [5, 6]. Thus, macrophage 
activation is transitory and can be resolved into a state 
such as bacterial tolerance, where pro-inflammatory 
mediator genes are silenced while antimicrobial effector 
genes are primed [7].
Tripartite motif (TRIM) family proteins share 
an N-terminal tripartite motif that consists of a RING 
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domain, one or two B-boxes and a coiled-coil domain and 
most TRIM family members have an E3 ubiquitin ligase 
activity. Numerous members of the TRIM family have 
been implicated in various innate signaling pathways both 
in the cytoplasm and in the nucleus. TRIM33 (TIF1γ, 
Ectodermin) belongs to a sub-family of chromatin binding 
TRIM proteins [8] that also includes TRIM24 (TIF1α), 
TRIM28 (TIF1β, KAP1) and TRIM66 (TIF1δ). The 
importance of TRIM33 in hematopoiesis was revealed 
by a genetic study of bloodless zebrafish mutants called 
moonshine that display cell-autonomous defects in primitive 
and definitive adult hematopoiesis [9]. In adult mice, 
targeted deletion of Trim33 in hematopoietic stem cells 
(HSC) affects the HSC compartment and promotes the 
expansion of Granulocyte-Monocyte Progenitors (GMP) at 
the expense of Common Myeloid Progenitors (CMP) and 
Megakaryocyte-Erythrocyte Progenitors (MEP) [10-12]. 
At the molecular level, interactions between TRIM33 
and GATA1, TAL1 or PU.1 regulate the function of these 
hematopoietic regulators [12, 13].
The PU.1/TRIM33 interaction together with the 
role of PU.1 in the chromatin changes that occur during 
macrophage production and in macrophages before and 
during the initiation of the inflammatory response [14] and 
the hematopoietic phenotype of mice deficient for TRIM33 
in hematopoietic cells suggest that TRIM33 may regulate 
myeloid fate and have a role in macrophage. Recently, 
three studies have indicated such a role of TRIM33. 
TRIM33 was shown (i) to interact and ubiquitinate DHX33 
and be essential for the DHX33-NLRP3 inflammasome 
complex [15], (ii) to bind an Ifnb1 regulatory region 
that acted as a repressor of the Ifnb1 gene at the end of 
bone marrow derived macrophage (BMDM) activation 
by LPS [16] and (iii) to be involved in late stages of 
granulomonopoiesis [17]. Here, we characterize the role of 
TRIM33 in macrophage production and activation using 
chromatin immunoprecipitation (ChIP) coupled to deep 
sequencing (ChIP-seq) analyses and two mouse models of 
Trim33 inactivation.
RESULTS
Differential TRIM33 chromatin binding in 
immature versus mature myeloid cell lines
To get insight into the role of TRIM33 in myeloid 
cells, we first studied, by ChIP-seq, TRIM33 binding 
to chromatin in murine immature myeloid 32D and 
monocyte/macrophage RAW 264.7 (RAW) cell lines. 
This analysis identified 21936 and 8304 TRIM33 peaks 
associated with 10454 and 5537 genes in 32D and RAW 
cells respectively (Figure 1A). TRIM33 peaks were 
enriched at promoter/transcriptional start sites (TSS) 
(Supplementary Figure S1A, left panels), with a higher 
TRIM33 occupancy of the TSS in RAW compared to 
32D cells (Supplementary Figure S1A, right panels). 
The proportion of overlapping TRIM33 peaks between 
the two cell types was relatively small (2443 peaks), 
representing 11% of total peaks in 32D cells and 29% 
of total peaks in RAW cells. However, analysis of genes 
associated with the nearest TRIM33 peak showed that the 
number of common TRIM33-bound genes was higher than 
expected regarding the number of overlapping peaks. It 
corresponded to 3652 genes, i.e. 35% and 66% of total 
TRIM33-bound genes in 32D and RAW cells (Figure 
1A, right Venn diagram, Supplementary Figure S1B). 
Altogether, these results show a higher number of TRIM33 
binding sites in immature myeloid cells and different 
binding sites of TRIM33 on same genes in immature and 
mature myeloid cells.
To characterize the TRIM33 peaks in immature 
and mature myeloid cells, we performed de novo motifs 
analysis. The PU.1 binding motif was the most enriched 
motif found at TRIM33 peaks in 32D (80%) and RAW 
(86%) cells (Figure 1B). Comparison with published 
PU.1 ChIP-seq data from BMDM [18] showed that 
50% and 65% of TRIM33 peaks in 32D and RAW cells, 
respectively, overlapped with PU.1 binding sites in 
BMDM (Figure 1C, left panel). Finally, in 32D cells, 42% 
of genes that shared TRIM33 and PU.1 binding sites had 
a single TRIM33 peak whereas 92% of these genes had 
more than one PU.1 peak in BMDM (Figure 1C, right 
panels). In RAW cells 76% of genes that shared TRIM33 
and PU.1 binding sites had a single TRIM33 peaks 
whereas 91% of these genes exhibited multiple PU.1 peaks 
(Figure 1C, right panels). Altogether, these results indicate 
that TRIM33 might be recruited on specific subsets of 
PU.1 binding sites in 32D and RAW cells.
To identify sequence determinants of these subsets 
of TRIM33/PU.1 binding sites, we investigated the 
occurrence of several myeloid-determining transcription 
factors motifs within 100bp of these binding sites and 
compared with their occurrence in randomly selected PU.1 
peaks. In 32D cells, this analysis showed that TRIM33/
PU.1 binding sites were enriched for GATA, RUNX, 
CEBP motifs and to a lesser extend AP1 motifs whereas, 
in RAW cells, TRIM33/PU.1 sites were enriched in motifs 
for CEBP and AP1 motifs (Figure 1D and Supplementary 
Figure S1C for control motifs). TRIM33 binding at PU.1 
binding sites might therefore require binding of different 
lineage-determining transcription factors in immature and 
mature myeloid cells.
As PU.1 can maintain nucleosome depletion 
at macrophage-specific enhancers [19], we analyzed 
association of TRIM33 peaks found in 32D and RAW cells 
with nucleosome occupancy in BMDM. We found that 
TRIM33 peaks correlated with nucleosome-free regions 
associated with PU.1 binding in BMDM only in RAW cells 
(Figure 1E), a property highly increased when TRIM33/
PU.1/AP1 binding sites were analyzed (Supplementary 
Figure S1D). This result indicated that TRIM33 might be 
recruited at nucleosome free macrophage-specific regions 
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Figure 1: Dynamics of TRIM33 binding in myeloid cell lines. A. Venn diagrams of TRIM33 peaks (left) and associated genes 
(right) in 32D and RAW cells. The number of cell-specific or co-localized peaks and shared genes are shown for each cell line. B. Most 
enriched sequence motifs in TRIM33 peaks in 32D and RAW cells. E-values on the significance of the motifs are given. The percentages 
of non-overlapping sites (p< 0.0001) are given in parentheses. C. (Left) Overlap between TRIM33 peaks in 32D and RAW cells and PU.1 
peaks in BMDM (data sets from [18]). (Right) Distribution of genes according to their numbers of associated TRIM33 and PU.1 peaks in 
32D and RAW cells. D. Occurrence of the indicated transcription factor binding sites in the different TRIM33/PU.1 peak subsets in 32D 
(green) and RAW (blue) cells compared to their frequency in random PU.1-bound regions in BMDM (red). Transcription factor matrices 
were extracted from Homer database and analyzed with RSAT Matrix-scan, using a threshold p-value<1e-4. E. MNase profiles in BMDM 
(data sets from [19]) around the summit of TRIM33 peaks in 32D (blue) or RAW (green) cells and around the summit of PU.1 peaks in 
BMDM (red). F. (Left) PU.1 binding sites in macrophages were clustered according to their TRIM33 ChIP-seq profiles in 32D and RAW 
cells. (Right) Gene Ontology (GO) functional annotation analysis of the three clusters of TRIM33/PU.1 target genes.
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enriched in PU.1/AP1 binding sites in mature myeloid 
cells.
Integrative analysis of TRIM33 ChIP-seq data in 
32D and RAW cells and PU.1-occupied sites in BMDM 
identified at least three major clusters (Figure 1F, left 
panel). Interestingly, one of these clusters, corresponding 
to TRIM33/PU.1 binding sites specific to RAW cells, 
was highly enriched in genes expressed in monocytes 
and macrophages and involved in inflammatory response 
(Figure 1F, right panels and Supplementary Figure S1E) 
suggesting a specific role of TRIM33 in macrophages.
TRIM33 deficiency at early stages of 
hematopoiesis is associated with impaired 
monocyte/macrophage production
To characterize the role of TRIM33 in immature 
and mature myeloid cells, we first used MxCre/Trim33-/- 
mice where deletion of Trim33 is induced, in all 
hematopoietic cells, by PIPC treatment of adult mice. 
One month after PIPC treatment, in their bone marrow 
(BM), MxCre/Trim33-/- mice had increased percentages 
of Granulocyte-Macrophage Progenitor (GMP) [12], 
but also of Monocyte/Macrophages and Dendritic cells 
Precursor (MDP) and of common MOnocyte Precursor 
(MOP) compared to MxCre/Trim33+/fl mice treated with 
PIPC (named MxCre/Control hereafter) (Figure 2A, left 
panel). As for mature myeloid cells, these mutant mice 
had an increased percentage of neutrophils (Figure 2A, 
middle panel), a ten-fold decreased percentage of Ly6Chigh 
monocytes and similar percentage of Ly6Clow monocytes 
(Figure 2A, right panel), both populations harboring 
complete deletion of Trim33 (Supplementary Figure 
S2A). In accordance with the BM cellular composition, 
MxCre/Trim33-/- mice displayed, in peripheral blood 
cells, a six-fold decreased percentage of inflammatory 
monocytes Ly6Chigh, a two-fold increased percentage of 
neutrophils and a two-fold decreased percentage of B 
lymphocytes when compared to MxCre/Control mice 
(Supplementary Figure S2B).
To analyze the effect of TRIM33 deficiency on 
resident and inflammatory macrophages, we studied the 
peritoneal macrophages population that contains large 
peritoneal macrophages (LPM), derived from embryonic 
precursors and/or monocytes, and small peritoneal 
macrophages (SPM), derived from monocytes during 
inflammation [20]. MxCre/Control and MxCre/Trim33-/- 
mice had a similar number of LPM in the peritoneal 
cavity (Figure 2B, left panel) and, in accordance with 
their origin, these LPM only harbored a partial deletion 
of Trim33 (Figure 2B, right panel). After thioglycollate-
induced peritonitis, the number of SPM was three-fold 
reduced in MxCre/Trim33-/- mice compared to MxCre/
Control mice (Figure 2C, left panel) and these SPM had 
a complete deletion of Trim33 (Figure 2C, right panel). 
Altogether, these results suggest that TRIM33 deficiency 
in hematopoietic cells was associated with impaired 
production of monocytes/macrophages.
When MxCre/Control and MxCre/Trim33-/- BM 
were grown in the presence of CSF-1 to generate bone 
marrow derived macrophages (BMDM), a decreased 
production of BMDM from MxCre/Trim33-/- BM was 
found (Supplementary Figure S2C, upper panel). This 
decrease correlated with decreased number of monocytes 
Ly6Chigh found in MxCre/Trim33-/- BM (Figure 2A, right 
panel). Although MxCre/Trim33-/- macrophages were 
F4-80+/CD64+, their morphology was different from 
MxCre/Control macrophages (Supplementary Figure 
S2C, lower panel). To study the myeloid differentiation 
of MxCre/Trim33-/- BM progenitors, we investigated their 
differentiation in the presence of GM-CSF or G-CSF. In 
the presence of GM-CSF, less clusters of dendritic cells 
and less F4-80+/CD64+ macrophages were obtained with 
MxCre/Trim33-/- BM (Supplementary Figure S2D) but 
MxCre/Trim33-/- and MxCre/Control derived dendritic 
cells had similar morphology (not shown). When 
MxCre/Trim33-/- BM was grown in the presence of G-CSF, 
very few F4-80+/CD64+ macrophages could be obtained 
with MxCre/Trim33-/- BM (Supplementary Figure S2E, 
upper panel). Altogether, these results indicate that the 
decreased number of macrophages found is correlated 
with the decreased number of monocytes found in 
MxCre/Trim33-/- BM but also suggest that TRIM33 
deficiency in hematopoietic cells diminished their capacity 
to produce macrophages.
To study the role of TRIM33 specifically in 
mature myeloid cells, Trim33fl/fl mice were crossed with 
mice expressing the Cre recombinase gene from the 
endogenous Lysozyme2 locus (LyzCre). In this mouse 
model (hereafter referred to as Trim33-/- mice), Trim33 
was targeted only in mature myeloid cells (Figure 2D) 
[21]. Trim33-/- mice did not display developmental 
abnormalities and were healthy. No difference in 
percentage of myeloid progenitors/precursors and mature 
myeloid cells could be detected in Trim33-/- and LyzCre 
Control BM (Figure 2E). LyzCre Control (named Control 
hereafter) and Trim33-/- mice had the same number of 
LPM in the peritoneal cavity (Figure 2F, left panel), the 
majority of which harboring deletion of Trim33 (Figure 
2F, right panel). After thioglycollate-induced peritonitis, 
the number of SPM in Control and Trim33-/- mice was 
similar (Figure 2G, left panels) and these SPM were 
all deleted for Trim33 (Figure 2G, right panel). Finally, 
BMDM obtained from Control and Trim33-/- BM were 
similar both in number (not shown) and morphology 
(Supplementary Figure S2F).
Altogether, these results show that TRIM33 
expression at early but not late stages of myeloid 
differentiation is necessary for efficient production of 
monocytes/macrophages.
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Characterization of gene expression during LPS 
activation of Trim33-/- BMDM
ChIP-seq analysis in RAW and 32D cells identified 
genes containing PU1/TRIM33 binding sites and involved 
in the inflammatory response only in RAW cells (Figure 
1F and Supplementary Figure S1E). These results 
indicated that, in addition to its role in the production 
of monocytes/macrophages, TRIM33 might also shape 
the transcriptional activity of macrophages before and/
or after activation. We therefore used Trim33-/- mice 
to globally characterize the role of TRIM33 in BMDM 
before and after LPS activation, using cDNA microarrays. 
In the absence of activation, 82 transcripts were down-
regulated and 93 up-regulated (Fold change FC 2, 
p<0.05) in Trim33-/- compared to Control BMDM (Figure 
3A and Supplementary Table S1). Most of the genes 
with the highest FC (FC 4, p<0.05) were up-regulated 
in Trim33-/- BMDM and more than 75% of these genes 
had at least one associated TRIM33 peak in RAW cells 
(Supplementary Table S2). Indeed, ChIP-qPCR analysis 
in immortalized Trim33-/- macrophages rescued with full-
length TRIM33 protein showed TRIM33 binding to these 
genes in macrophages (Supplementary Figure S3A). The 
changes in expression of genes with FC>4 were confirmed 
by RT-qPCR in BMDM (Figure 3B, upper panels) and in 
thioglycollate-elicited peritoneal macrophages (Figure B, 
lower panels). Altogether, these results indicate that 
TRIM33 mainly acts as a transcriptional repressor in 
macrophages in vitro and in vivo.
As cell surface expression of TLR4 was similar 
in Control and Trim33-/- BMDM (Supplementary Figure 
S3B), we studied the consequences of TRIM33 deficiency 
during LPS activation of BMDM. Microarray analysis 
(FC 2, p<0.05) showed that, 4h after LPS activation, the 
number of deregulated genes in LPS-activated Trim33-
/- BMDM represented a small percentage (7%) of the 
genes induced or repressed by LPS treatment in Control 
BMDM (Figure 3C, right panels). This result indicated 
that early TLR4 triggered signaling pathways were not 
grossly modified by TRIM33 deficiency. Accordingly, 
early kinetics of the level of mRNAs coding for 
several inflammatory cytokines or known regulators of 
macrophage functions were similar in Control and Trim33-
/- BMDM activated with LPS (Supplementary Figure S3C).
Four hours after LPS activation of Trim33-/- BMDM, 
the total number of down-regulated genes increased 
5-fold and the total number of up-regulated genes 
Figure 2: Role of TRIM33 during myeloid differentiation. A. Box plots of indicated bone marrow (BM) hematopoietic populations 
of MxCre/Control and MxCre/Trim33-/- mice. GMP (Granulocyte-Macrophage Progenitor) (Lin-, Sca1-, c-Kit+, CD16/32+, CD34+), 
MDP (Monocyte/Macrophages and Dendritic cell Precursor) (Lin-, CD115+, CD117+, CD135-), MOP (common MOnocyte Precursor) 
(Lin-, CD115+, CD117+, CD135+), neutrophils (CD11b+, (F4-80,I-A(b), CD11c)med, Ly6Ghigh), and monocytes (SSClow, B220-, (F4-80,I-
A(b), CD11clow), CD115+, Ly6Chigh/low). n=9-12 mice, ***p<0.0006, **p<0.001, *p<0.02 (Mann-Whitney test). B. (Left) Total number 
of Large Peritoneal Macrophages (LPM), (B220-, CD11c-, CD11b+, F4-80high) in MxCre/Control and MxCre/Trim33-/- mice. n=4-9 mice, 
***p<0.0002 (Mann-Whitney test). (Right) Genomic PCR from MxCre/Control and MxCre/Trim33-/- LPM for Trim33 floxed and Trim33 
excised allele. Only relevant bands are shown. C. (Left) Total number of Small Peritoneal Macrophages (SPM) (B220-, CD11c-, CD11b+, 
F4-80+) with thioglycollate induced peritonitis in MxCre/Control and MxCre/Trim33-/- mice. n=4-9 mice, ***p<0.0002 (Mann-Whitney 
test). (Right) Genomic PCR from MxCre/Control and MxCre/Trim33-/- SPM for Trim33 floxed and Trim33 excised allele. Only relevant 
bands are shown. (Continued ) 
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increased 3-fold when compared to non-activated BMDM 
(Figure 3C, left panels). Interestingly, down-regulated 
genes were overrepresented among those induced by LPS 
in Control BMDM (Figure 3C, upper right panel), whereas 
up-regulated genes were overrepresented among those 
repressed after LPS activation (Figure 3C, lower right 
panel). These results indicated that TRIM33 deficiency in 
BMDM was associated with an impaired transcriptional 
response of a subset of genes in the early response to LPS. 
To characterize this subset, a Gene Ontology analysis was 
performed and showed a specific enrichment of genes 
involved in wound healing, such as Nos2 (down-regulated 
genes) or in organelle fission, such as Fis1 (up-regulated 
genes) (Supplementary Figure S3D).
At the end of LPS activation of BMDM, i.e. 24 
hours after this activation, 170 transcripts were down-
regulated and 279 up-regulated in Trim33-/- BMDM. 
Compared to 4 hours, the number of down-regulated 
genes in Trim33-/- BMDM (FC 2, p<0.05) at 24 hours 
decreased (Figure 3D, left panel) and 60% of these 
genes were already down-regulated before or 4 hours 
after LPS activation (Figure 3D, right panel and Table 
S3). In contrast, the number of up-regulated genes in 
Trim33-/- BMDM was similar after 4 and 24 hours of 
LPS activation (Figure 3E, left panel), but only 30% of 
the genes up-regulated at 24 hours were up-regulated 
before or 4 hours after LPS activation (Figure 3E, right 
panel and Table S3). This indicated that TRIM33 might 
be required for repression of a distinct subset of genes at 
the end of LPS stimulation of BMDM.
Microarray analyses and TRIM33 ChIP-seq 
data in RAW cells, highly correlated with TRIM33 
binding in BMDM 24 hours after LPS activation 
(Supplementary Figure S3E), showed that 30% (83 
out of 279) of genes up-regulated 24 hours after LPS 
activation of Trim33-/- BMDM were associated with at 
Figure 2: (Continued ) Role of TRIM33 during myeloid differentiation. D. Schema of myeloid differentiation, Lysozyme 
expression and generation of Trim33-/- mice. HSC (Hematopoietic Stem Cell) and CMP (Common Myeloid Progenitor)  E. Box plots of 
indicated hematopoietic populations from BM of  Control and Trim33-/- mice. n=8-15 mice. F. (Left) Total number of large peritoneal 
macrophages (LPM) in Control and Trim33-/- mice. n=3-9 mice. (Right) Genomic PCR from Control and Trim33-/- LPM for Trim33 
floxed and Trim33 excised allele. Only relevant bands are shown. G. (Left) Total number of small peritoneal macrophages (SPM) with 
thioglycollate induced peritonitis in Control and Trim33-/-   mice. n=3-9 mice. (Right) Genomic PCR from Control and Trim33-/- SPM for 
Trim33 floxed and Trim33 excised allele. Only relevant band are shown.
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least one TRIM33 peak (Table S3) and 86% of these 
TRIM33-target genes shared a PU.1/TRIM33 binding 
site (Table S3). GREAT analysis of these TRIM33-target 
genes showed a specific enrichment of genes involved 
in purinergic nucleotide receptor activity and in lipid 
metabolism (Figure 3F), including important regulators 
at the end of inflammatory response of BMDM, such 
as P2rx7, P2ry12, P2ry14, Abcg1, Cd36, Serpine1, 
VEGFa, Esr1 and OX40 ligand (Tnfsf4) (Figure 3G and 
Supplementary Figure S3F).
Altogether, these results indicate impaired 
repression of pathways regulating the late phases of 
lipopolysaccharide (LPS) activation of BMDM in TRIM33 
deficient BMDM.
Figure 3: TRIM33 regulates gene expression of a subset of genes in BMDM. A. Gene expression changes in Trim33-/- versus 
Control BMDM (green: down-regulated genes; red: up regulated genes; FC 2; p<0.05). B. Relative mRNA levels in BMDM (top) and 
thioglycollate-elicited peritoneal macrophages (PM) (bottom) of genes with the highest FC (FC>4, p<0.05) were measured by quantitative 
RT-PCR. Data are the average fold changes relative to Control BMDM or PM ± SEM. Genes harboring TRIM33 peaks in RAW cells are 
indicated. C. Number of down- and up-regulated genes (FC 2; p<0.05) in Trim33-/- BMDM before (0h) and 4h after LPS activation (left 
histograms). Overlap between down-regulated or up-regulated genes in Trim33-/- BMDM and LPS-induced (upper panel) or -repressed 
(lower panel) genes 4 hours after LPS activation. D. (Left) Number of down-regulated genes (FC 2; p<0.05) in Trim33-/- BMDM at 
indicated time points after LPS activation and (right) overlapping of down-regulated genes before (0h), 4h and 24h after LPS activation 
of BMDM. E. (Left) Number of up-regulated genes (FC 2; p<0.05) in Trim33-/- BMDM at indicated time points after LPS activation and 
(right) overlapping of up-regulated genes before (0h), 4h and 24h after LPS activation of BMDM. F. GREAT functional annotation analysis 
of the genes harboring TRIM33 peaks in RAW cells and up-regulated (FC 2; p<0.05) in Trim33-/- BMDM 24h after LPS activation. G. 
Relative mRNA levels in BMDM of indicated genes measured by quantitative RT-PCR after 24h of LPS activation. Mean ± SEM, n=3.
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Impaired response of Trim33-/- mice to an 
endotoxin challenge
The effects of TRIM33 deficiency on gene 
expression in BMDM and PM suggested that the in vivo 
response of Trim33-/- mice to LPS might be altered. We 
therefore treated Control and Trim33-/- mice with a sub-
lethal dose of LPS. All Control animals survived to this 
endotoxin challenge, whereas only 28% of Trim33-/- mice 
survived (Figure 4A). This decreased survival was not 
associated with any difference in the plasma levels of IL6, 
MCP-1, TNFα, IFNγ and IL1β (Figure 4B) in the early 
phase of cytokine production. However, mortality was 
associated with increased plasma levels of IL6, MCP-1 
and TNFα during the late phase of the endotoxin challenge 
in Trim33-/- mice (Figure 4C) suggesting impaired 
functions of LPS activated Trim33-/- myeloid cells at the 
end of this endotoxin challenge.
DISCUSSION
TRIM33 has essential roles in mouse hematopoietic 
stem cells and multiple blood lineages and is involved in 
macrophage function and inflammation. Indeed, TRIM33 
has been shown to regulate NLRP3 inflammasome 
activation in response to bacterial or viral infection 
[15] through a direct interaction with DHX33 in the 
cytoplasm and to regulate Ifnb1 transcription at the late 
stages of BMDM activation [16]. Here, we extend this 
role by showing that TRIM33 regulates the production of 
macrophages and is also involved in the innate immune 
response by the regulation of a subset of genes in BMDM 
and primary macrophages activated with LPS.
ChIP-seq analysis of TRIM33 in murine immature 
and mature myeloid cell lines showed that TRIM33 
recruitment was enriched over the transcription start site, 
a property also found in testis [22]. TRIM33 is not thought 
to bind DNA directly and our study revealed a preferential 
association of TRIM33 with PU.1 binding sites in 32D and 
RAW cell lines. Recently, ChIP-seq analysis of TRIM33 in 
murine B cell leukemia (B-ALL) has shown that TRIM33 
is concentrated, in the B-ALL genome, at a small number 
of sites characterized by a high density of sequence motifs 
recognized by PU.1 [23]. Our analysis in 32D and RAW 
cell lines revealed that TRIM33 was mostly recruited on 
a large subset of PU.1 binding sites flanked by motifs for 
different myeloid-determining factors, including GATA, 
RUNX, CEBP in 32D cells and CEBP and AP1 in RAW 
cells. This discrepancy might be related to a different 
recruitment of TRIM33 in myeloid and B-lymphoid cells, 
Figure 4: TRIM33 deficiency is associated with high sensitivity to endotoxin challenge. A. Survival curves of Control and 
Trim33-/- mice after intra-peritoneal injection of LPS (0.25mg/20g). (n=8-9 mice for each group). * p<0.02 (Gehan-Breslow-Wilcoxon test). 
B. Kinetics of serum concentrations of the indicated cytokines after intra-peritoneal injection of LPS. Mean ± SEM, n=5 mice. C. Fold 
increase of IL6, MCP1 and TNFα in serum of dying Trim33-/- mice versus Control mice (serum collected just before the death of Trim33-/-
 mice) (n=3 vs 5).
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discrepancy related to the different transcription factors 
that increased TRIM33 recruitment on specific PU.1 sites.
The two strongest sites of TRIM33 enrichment 
in B-ALL were located 117bp upstream of Bcl2l11/Bim 
gene (in an intron of Acoxl gene), and at a site 35 kb 
upstream of Atp1b3. We also found TRIM33 recruitment 
to these sequences in 32D and RAW cell lines, with 
additional TRIM33 peaks at the Bcl2l11/Bim locus in 
myeloid compared to lymphoid cells (Supplementary 
Figure S4A). In B-ALL cells, Atp1b3 and Bcl2l11/Bim, 
but not Acoxl, genes expression is highly increased upon 
TRIM33 knock-down. TRIM33 deficiency in BMDM 
and peritoneal macrophages was also associated with 
an increased expression of Atp1b3 and Bcl2l11/Bim 
(Table S3). Interestingly, Acoxl, although only weakly 
expressed in Control BMDM, was strongly up-regulated 
in activated Trim33-/- BMDM. Altogether, these results 
suggest a repressive effect of TRIM33 on the expression 
of Atp1b3 and Bcl2l11/Bim genes both in myeloid and 
lymphoid lineages. However, as illustrated by the Acoxl 
gene regulation, the mechanisms of repression might be 
different and related to different chromatin structure in the 
two lineages.
TRIM33 deficiency in immature myeloid cells 
impaired the production of monocytes/macrophages 
both in vitro and in vivo. This result is in accordance 
with a recent study that showed that Trim33 knock-out 
in hematopoietic cells results in abnormal monocyte 
and macrophage maturations associated with decreased 
expression of the CSF-1 receptor [17]. We did not find 
CSF1-R decreased expression in MxCre/Trim33-/- mice 
(data not shown) although TRIM33 peaks were present 
in the Csf1-R gene with one peak within the Csf1-R 
intronic enhancer [24] (Supplementary Figure S4B). This 
discrepancy might be explained by the two conditional 
hematopoietic-specific Trim33 knock-out used. We used 
MxCre/Trim33-/- mice where Trim33 knock-out is induced 
by PIPC treatment of adult mice and whereas Chrétien et al. 
used cFES-Cre where Trim33 knock-out is constitutive 
during adult hematopoiesis and during development of 
the hematopoietic tissue. This differential Cre expression 
results in leukemia in the cFES-Cre mediated Trim33 
knock-out whereas MxCre/Trim33-/- mice never developed 
myelomonocytic leukemia. The decreased expression of 
the CSF-1 receptor might thus be related to this leukemic 
transformation.
TRIM33 deficiency in mature myeloid cells did 
not severely impair macrophage production and specific 
property of macrophages such as phagocytosis capability 
(data not shown). In addition, TRIM33 deficiency did 
not alter the early TLR4 triggered signaling pathways as 
shown by similar early kinetics of the level of mRNAs 
coding for several inflammatory cytokines or known 
regulators of macrophage functions in Control and Trim33-
/- BMDM activated with LPS. Recently, TRIM33 has been 
shown to be essential for the cytosolic dsRNA-induced 
NLRP3 inflammasome activation by targeting DHX3 
[15]. As NLRP3 is activated by various stimuli including 
LPS plus ATP treatment, but not by LPS treatment alone, 
these results indicated that TRIM33 might have different 
functions depending on the type of activation of BMDM.
Contrary to the early phases of LPS activation of 
BMDM, we showed that TRIM33 deficiency altered 
pathways that regulate the late phases of BMDM activation 
and of in vivo LPS-mediated inflammatory response. 
Resolution of inflammation in M1 macrophages depends 
on two main categories of regulators [25]. The first group 
contains inhibitors of signaling pathways activated by 
microorganisms such as suppressors of cytokine signaling 
or A20. The second group contains transcriptional 
repressors such as ATF3 or peroxysome proliferator-
activated receptors that repress the transcription of genes 
previously activated by microorganisms. Our results 
indicate that TRIM33 belongs to this second group of 
regulators. We have previously shown that TRIM33 
expression was necessary for repression of the Ifnb1 
gene during late phases of BMDM activation. Here, we 
extend this result and show that TRIM33 targets genes at 
the late stages of LPS activation of BMDM. These genes 
are not part of a single pathway but are involved in lipid 
metabolism (Abcg1, CD36 [26]), macrophage metabolism 
(estrogen receptor α (Esr1) [27]) and inflammatory 
response (purinergic receptor family, ATP-gated P2X7 
receptor [28], -P2y12 receptor [29] and -P2y14 receptor 
[30], VEGF-A and the OX40 ligand (Tnfsf4) [31]).
In conclusion, our study reveals new important 
functions of TRIM33 in macrophage production and 
activation by LPS and links the TRIM33/PU.1 association 
to transcriptional changes that occur during the end of 
macrophage response to bacterial infection. Together 
with the role of TRIM33 during viral infection [15], 




MxCre/Trim33-/- mice were previously described 
[12]. To generate Trim33-/-mice, Trim33fl/fl C57BL/6-
CD45.2 mice were crossed with Lysozyme-Cre C57/
Bl6-CD45.2 mice (strain name: B6.129P2-Lyz2tm1(cre)
Ifo/J, The Jackson Laboratory). Mice (6-16 weeks old) 
were injected intra-peritoneally with LPS (Sigma) 
according to mass per body weight (0.25mg/20g). 
Animal experiments were approved by the Committee 
on the Ethics of Animal Experiments according to 
the French Ministry of Agriculture (Act No.87-848, 




Mouse bone marrow (BM) was flushed out of 
the tibia, femur and humerus using a syringe with PBS, 
filtered through a 70-µm mesh filter (BD Biosciences) 
to remove debris and pelleted by centrifugation, and 
cleared of adherent cells by incubation for 3 hours on 
tissue culture Petri dishes. BM cells were then cultured on 
tissue culture Petri dishes in IMDM supplemented with 
10% FCS (Invitrogen), 1% penicillin streptomycin (PS) 
(Gibco), 10mM thioglycerol (Sigma) and 25ng/ml mouse 
CSF1 (Miltenyi Biotech) or 50 ng/ml GM-CSF (Miltenyi 
Biotech) or 20 ng/ml G-CSF (Miltenyi Biotec) for 7 days. 
On day 7, BMDM generated with CSF1 were activated 
with 100ng/ml LPS (Sigma) in IMDM supplemented with 
2.5% FCS and 1% PS.
Resident peritoneal cells present without or 4 days 
after injection of thioglycollate (Sigma) were harvested 
with PBS and cultured for 2 hours in RPMI medium, 
supplemented with 10% FCS and 1% PS. All adherent 
cells were positive for F4-80 antigen (data not shown) 
and were studied as peritoneal macrophages. The next 
day, peritoneal macrophages were activated with 100ng/
ml LPS (Sigma) in RPMI supplemented with 2% FCS and 
1% PS.
For cell lines, myeloid 32D cells were cultured in 
RPMI adjusted to contain 10 mM HEPES and 1.0 mM 
sodium pyruvate, supplemented with 10% FCS, 1% PS 
and mouse Interleukin-3 (Becton Dickinson). RAW 264.7 
cells were grown in DMEM supplemented with 10% FCS 
and 1% PS. All these cell lines were purchased in ATCC.
Flow cytometry
Single cell suspensions of BM were depleted of 
red blood cells using an ammonium chloride solution 
(STEMCELLTM). Cells were incubated for 20 min with, 
PECy7 anti-B220, FITC anti-(F4-80, I-A(b), CD11c), PE 
anti-CD115, APC anti-Ly6C for monocytes; PECy7 anti-
CD11b, FITC anti-(F4-80, I-A(b), CD11c), PE anti-Ly6G 
(eBioscience) for neutrophils. For progenitors populations, 
BM suspension cells were incubated with biotinylated 
lineage cell detection cocktail (Miltenyi Biotec) and 
revealed by streptavidin-eFluor450 (eBioscience) to 
discriminate between the positive and the negative 
lineages. The negative fraction was then labeled with 
FITC anti-CD34 (BD Biosciences), APC anti-c-Kit (BD 
Biosciences), PE anti-Sca-1 (BD Biosciences) and PECy7 
anti-CD16/32 (eBioscience) antibodies for CMP and 
GMP analyses. For MDP and MOP analyses BM cells 
were labeled with APC-efluor780 anti-c-Kit, PE anti-
CD115 and APC anti-CD135 antibodies (eBioscience). 
Peritoneal macrophages were labeled with PE anti-B220, 
FITC anti-F4-80, PECy7 anti-CD11b and APC anti CD11c 
antibodies (eBioscience). BMDM and dendritic cells from 
BM cultures were labeled with FITC anti-CD11c, PC7 
anti-Ly6G, APC anti-CD11b, APC-Cy7 anti-F4-80 and 
PerCP5.5 anti-CD64.
Plasma levels of cytokines were quantified by 
flow cytometry (CBA Mouse inflammation kit, BD 
Biosciences).
Data acquisition was performed on FACS LSR 
II (BD Biosciences). Data were analyzed with FlowJo 
software version 9.5. Sorting cells were performed on 
FACS Aria II (BD Biosciences).
Quantitative RT-PCR
Total RNA was extracted with the RNeasy Micro 
Plus kit (QIAGEN) and reverse transcribed with random 
primers and Superscript III (Invitrogen). Real-Time 
quantitative PCR was performed using the SYBR green 
in the 7900HT Fast Real-Time PCR System (Applied 
Biosystems). HPRT mRNA levels were used as an internal 
reference. Primer sequences are available upon request.
cDNA microarrays and analysis
Total RNA was extracted with the RNeasy 
Micro kit (QIAGEN). Gene expression profiling was 
performed in biological duplicates on Mouse GE 8x60K 
Microarrays (Agilent) according to the manufacturer’s 
instructions. Accession number (E-MTAB-1441, 
European Bioinformatic Institute (http://www.ebi.ac.uk/
arrayexpress/).
The Bioconductor package LIMMA was used to 
assess statistical significance of differences in mRNA 
levels between Trim33-/- and Control macrophages. 
Transcripts with at least two-fold change and p-value<0.05 
were retained as differentially regulated. Subsequent 
analyses were limited to probe sets matching a known 
transcript.
Chromatin immunoprecipitation and sequencing
ChIP experiments were carried out with an anti-
TRIM33 antibody (A301-059A, Bethyl) as previously 
described [12]. For sequencing, 10ng of purified DNA 
from ChIP was adapter-ligated, PCR amplified and 
sequenced by Illumina Genome Analyzer IIx according 
to the manufacturer’s instructions (Illumina). Accession 
number (GSE43654).
The libraries were sequenced on the Illumina 
Genome Analyzer IIx as single-end 50 base reads 
following Illumina’s instructions. Image analysis and 
base calling were performed using the Illumina Pipeline 
and sequence reads mapped to reference genome mm9/
NCBI37 using Bowtie v0.12.7. In order to keep just 
the reads mapping to a unique position in the genome, 
Bowtie was run with the option –m 1. The option –best 
–strata were also used to get the best mapping position 
with the minimum of mismatch. In order to define the 
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TRIM33 enriched genomic regions, peak calling was 
performed using MACS [32] with default parameters and 
using the corresponding IgG as control samples. Peaks 
were then annotated according to genomic features of 
Ensembl v67 using Homer [18] (http://homer.salk.edu/
homer/). For co-localization studies, the TRIM33 peak 
positions of 32D and RAW cells and the PU.1 peaks in 
BMDM were intersected using BEDTools, requiring 
at least 1bp overlap. MEME-ChIP [33] (http://meme-
suite.org/tools/meme-chip) was used to perform de 
novo motif discovery in TRIM33 peaks. Sequences 
spanning from -100bp to +100bp relative to the 600 
highest enriched ChIP-Seq peak centers were extracted 
and repeat masked. The MEME algorithm was then 
used to identify motifs with a maximum size of 15bp 
and known motifs were derived from JASPAR and 
uniprobe databases. RSAT Matrix-Scan (http://rsat.ulb.
ac.be/) was used to analyze TRIM33 and TRIM33/PU.1 
peaks for transcription factor binding sites. Transcription 
factor matrices were extracted from Homer database and 
the occurrence was analyzed using a threshold p-value 
< 1e-4. The enrichment of Gene Ontology terms was 
calculated using DAVID tools or GREAT.
Comparisons between 32D and RAW ChIP-
seq datasets at selected regions were performed using 
seqMINER [34]. Genomic coordinates were retrieved 
from Ensembl v67 and used as reference in the density 
array method. The collected data were subjected to 
k-means clustering using linear normalization. Data were 
represented as heat maps or average plots.
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